Investigating a new pathway that helps triple-negative breast cancer grow and spread
Official title: A novel cellular identity regulatory pathway that drives anokis resistance-mediated TNBC growth and metastasis
Funded at University of Alabama at Birmingham · NIH-10947156 · Data updated 2026-11-12
This study is looking at how triple-negative breast cancer cells manage to survive when they should die after breaking away from their surroundings, and by finding certain proteins that help them do this, the researchers hope to discover new ways to treat this tough type of breast cancer.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $148,500 |
| NIH project number | 1R03CA292128-01 |
| Project ID | NIH-10947156 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with triple-negative breast cancer, particularly those with advanced or metastatic disease.
✕Less likely to help
Patients with non-triple-negative breast cancer subtypes may not benefit from this research.
What this research studies
This research focuses on understanding how triple-negative breast cancer (TNBC) cells resist a process called anoikis, which normally causes cells to die when they detach from their surroundings. By identifying specific protein kinases that contribute to this resistance, the study aims to uncover new therapeutic targets for TNBC treatment. The researchers will use advanced screening techniques to pinpoint these kinases and evaluate their role in TNBC growth and metastasis. This could lead to the development of more effective treatments for patients suffering from this aggressive form of breast cancer.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies that significantly improve outcomes for patients with triple-negative breast cancer.
How similar studies have gone: Previous research has successfully identified therapeutic targets in other cancer types using similar approaches, suggesting potential for success in this area as well.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Gupta, Romi — University of Alabama at Birmingham
- Study coordinator: Gupta, Romi
Related research
Other NIH-funded projects on the same topics.
-
Lymph node metastasis and immune tolerance in head and neck cancer
A study in people with head and neck cancer looks at how cancer spread to lymph nodes may shape the immune system and help tumors grow.
-
Targeting how RMS cells fail to mature to slow or stop pediatric muscle cancer spread
A project to understand why a pediatric muscle cancer called rhabdomyosarcoma spreads, and to test ideas that could slow or stop it by helping cancer cells mature properly.
-
Centers studying how cancer spreads through the body
A multi-institutional project at Rockefeller University is exploring how nerves, blood vessels, lymphatics, immune cells, and metabolites influence the spread of cancer to help identify new ways to stop metastasis.
-
Angiopoietin-2 and Tie2 signals shaping liver metastasis in pancreatic neuroendocrine tumors
A study explores how Angiopoietin-2 and the Tie2 receptor influence the spread of pancreatic neuroendocrine tumors to the liver and how this affects responses to immunotherapy.
-
Nanoparticles that boost MRI to find tiny brain metastases
This uses tiny magnetic nanoparticles and new MRI image processing to help doctors find very small brain metastases earlier in people with cancer.
-
Tumor-Niche Co-evolution in Ovarian Cancer Metastasis and Resistance
This research explores how ovarian cancer cells interact with their surrounding tissue to understand how metastasis and resistance to therapy develop, with potential to guide better treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.